Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study-Reference-Cited by-同舟云学术

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study

Published:2020-04-23 Issue:6 Volume:36 Page:947-958
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Shingaki Tomotaka¹^ORCID,Taki Kentaro¹,Koyanagi Momoha¹,Nagaoka Soshi¹,Yoshizawa Kenichi¹,Oki Norika¹,Yoshikawa Aki¹,Imaoka Takeshi¹

Affiliation:

1. Medicines Development Unit-Japan, Eli Lilly Japan K. K, Kobe, Japan

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1754182

Reference32 articles.

2. Biosimilar Insulin and Costs

3. Eli Lilly and Company: FDA grants tentative approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection) [Internet]. Indianapolis (IN): Eli Lilly and Company, 2014, Aug 18

4. [cited 2019 May 28]. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=866751

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration;Pharmacoepidemiology;2024-03-01

2. Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region;Diabetes Therapy;2024-02-15

3. Insulin analogs in the treatment of type II diabetes and future perspectives;Disease-a-Month;2023-03

4. The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine;Clinical Therapeutics;2022-07

5. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience;BioDrugs;2022-05